TerminatedPhase 4

Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

Stopped: slow recruitment.

United States3 participantsStarted 2020-10-01

Plain-language summary

This is a pilot study designed to assess for relative change in cardiac 18F Florbetapir uptake in patients with AL cardiac amyloidosis after appropriate chemotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients aged \> 18 years are eligible.
✓. Patient must provide informed consent to participate in the study protocol.
✓. All patients must have clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or cardiac MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis).
✓. Planned plasma cell-directed chemotherapy.
✓. A negative pregnancy test will be required for all women of child bearing potential, breast feeding is not permitted.
✓. Patients must be able to undergo PET-CT imaging
✓. Patients must be able to complete 6-minute walk test

Exclusion criteria

✕. Severe claustrophobia
✕. Pregnancy
✕. Allergy to F-18 florbetapir

What they're measuring

Relative change in cardiac uptake of 18F florbetapir prior to chemotherapy and after six months of chemotherapy.

Timeframe: six months

Trial details

NCT IDNCT03333551

SponsorMedical College of Wisconsin

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-05-08

View on ClinicalTrials.gov More Cardiac Amyloidosis trials